Executive Summary
Franklin Biolabs provides manufacturing capabilities for high-titer, high-quality lentiviral (LV) vectors tailored for somatic cell therapy applications, including Chimeric Antigen Receptor (CAR-T) and T-cell receptor (TCR-T) engineering. We address the unique quality control, scalability, and regulatory requirements for ex vivo cell transduction. Our process ensures vector consistency and purity, supporting programs from preclinical development through multi-jurisdictional IND and IMPD submissions under harmonized ICH guidelines.
Frequently Asked Questions
Q: What are the primary quality attributes (CQAs) for lentiviral vectors used in TCR-T manufacturing?
Key CQAs for LV vectors in this context include functional titer, vector purity (absence of replication-competent lentivirus), p24 concentration, and transgene integrity. We establish a robust analytical profile for each batch to ensure consistent transduction efficiency and a well-defined safety profile for the final cell therapy product.
Q: How does Franklin Biolabs support the transition from preclinical to GxP-compliant vector production for cell therapies?
Our approach is built on phase-appropriate development. We begin with research-grade vector production to establish process parameters and then support the transition to manufacturing in GxP-compliant environments. This continuity is guided by a core scientific team with a 100% successful IND submission rate since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024.
Q: Can you accommodate custom vector constructs for novel TCR or CAR designs?
Yes. Our team specializes in custom projects, including novel and complex vector designs. We provide consultative support on construct optimization to maximize expression and functional performance in target immune cells, drawing from extensive experience generating thousands of unique vector constructs.
As an extension of our core viral vector capabilities detailed in our [AAV Research Vector Packaging Services](/aav-research-vector-production-packaging-services_11.md), Franklin Biolabs provides dedicated manufacturing for lentiviral vectors. These vectors are a primary tool for the stable genetic modification of hematopoietic and lymphoid cells, forming the foundation of many autologous and allogeneic cell-based advanced therapeutics.
Our production platform is specifically designed to meet the demands of TCR-T and other somatic cell therapy programs, where vector quality directly impacts the safety and efficacy of the final therapeutic product. We focus on generating high-titer vectors that achieve efficient ex vivo transduction while minimizing the potential for insertional mutagenesis.
Analytical Rigor for Complex Biologics
The characterization of lentiviral vectors requires a distinct set of analytical methods compared to other viral systems. Our quality control process includes a comprehensive panel of assays to define each vector lot.
-
Vector Titer and Potency: Functional titration assays to confirm transduction efficiency in relevant cell lines.
-
Purity and Safety: Rigorous testing for replication-competent lentivirus (RCL) and quantification of process-related impurities.
-
Identity: Confirmation of genetic payload integrity and vector identity via molecular methods.
This comprehensive analytical package is integrated into every production campaign, providing a robust data set to ensure lot-to-lot consistency and support regulatory submissions.
Applying Immunological Intelligence to Vector Design
While ex vivo transduction mitigates many in vivo immunogenicity concerns, understanding the potential for host immune responses remains a component of a thorough risk assessment. The principles of comprehensive immune profiling, such as those used to assess humoral and T-cell responses to viral vectors (PMID: 29668327), inform our analytical strategy. By applying this intelligence, we help sponsors build a more complete data package that anticipates potential immunological questions during regulatory review.
Our scientific leadership brings deep experience to these programs, guiding sponsors through the complexities of vector manufacturing to achieve an 18-24 month timeline to IND. This work is conducted within our expansive facilities, which include over 100,000 square feet of specialized laboratory and support space
. The core team’s historical performance, including collaborations with organizations like our partners, underpins our operational excellence.
